Seqens Seqens

X

Find the latest Drugs in Development and Pipeline Prospector News of Cinven Partners LLP.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Cinven Partners LLP
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
Warwick Court Paternoster Square London EC4M 7AG
Telephone
Telephone
+44 (0)20 7661 3333
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow

Details:

EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.


Lead Product(s): Sevasemten

Therapeutic Area: Genetic Disease Product Name: EDG-5506

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Edgewise Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MSP-2017 (etripamil), is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient.


Lead Product(s): Etripamil

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MSP-2017

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Milestone Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 17, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.


Lead Product(s): SLN360

Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360

Highest Development Status: Phase IProduct Type: Large molecule

Recipient: Silence Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Direct Biologics will leverage Bioclinica’s Interactive Response Technology (IRT) for their EXIT COVID-19 study, a multi-center FDA phase II clinical trial for the use of ExoFlo™ to treat COVID-19 acute respiratory distress syndrome (ARDS).


Lead Product(s): DB-001

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ExoFlo

Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Direct Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 09, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY